Search Results 1491-1500 of 19461 for Hemoglobin

  1. A Study to Evaluate Topical VT30 to Treat Patients with Venous/Lymphatic Malformations Associated with PIK3CA or TEK Gene Mutations - Mayo Clinic

    Hemoglobin A1c is > 8%. Any other clinically significant laboratory or testing abnormality that, in the opinion of the Investigator, might confound the ...

  2. Transforming stomach cancer care: 6 recent innovations - Mayo Clinic

    Other outcomes, including weight loss and hemoglobin levels, also were favorable." 4. Immunotherapy with, and possibly in place of, surgery. Immunotherapy is ...

  3. Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies - Mayo Clinic

    Hemoglobin ≥ 8 g/dL; Absolute neutrophil count (ANC) ≥ 0.75 x 10^3/uL without treatment with a myeloid growth factor within 3 days prior to first dose of ...

  4. MC200404, Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Late-stage Metastatic Colorectal Cancer - Mayo Clinic

    Hemoglobin ≥ 9 g/dL;; Total bilirubin ≤ 1.5 x ULN;; Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤3 x ULN (≤5 x ULN for patients with ...

  5. Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial) - Mayo Clinic

    Hemoglobin < 8.0 g/dl, uncorrectable INR > 3.05, or platelet count < 75,000/ml. Severe renal impairment (on chronic dialysis or estimated GFR < 30 ml/min) ...

  6. 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer - Mayo Clinic

    - Hemoglobin ≥ 9 g/dL - Hepatic: - Total bilirubin < 2 x the institutional upper limit of normal (ULN). For participants with known Gilbert's Syndrome ≤ 3 ...

  7. LS1681: A Study of AR160 in Treating Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

    Hemoglobin ≥ 8.0g/dL. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or if total bilirubinism. > 1.5 x ULN, the direct bilirubin ≤ ULN. Alkaline ...

  8. A Study to Evaluate the Effectiveness and Safety of Ralinepag To Improve Treatment Outcomes in Peripheral Arterial Hypertension (PAH) Patients - Mayo Clinic

    Hemoglobin concentration < 9 g/dL at Screening. Subjects treated with an IV or SC prostacyclin pathway agent (e.g., epoprostenol, treprostinil, or iloprost) ...

  9. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Hemoglobin* ≥ 9g/dL. Renal: eGFR (CKD-EPI calculation) ≥ 30 mL/min/1.73m^2. Hepatic: Serum total bilirubin ≤ 1.5 x ULN; or; Direct bilirubin ≤ ULN for ...

  10. LS138D, Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma - Mayo Clinic

    Hemoglobin > 10.0 g/dL; Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or if total bilirubin is > 1.5 x ULN, the direct bilirubin must be ≤ ULN ...